Sun Xiaona, Wu Yuxuan, Wang Xingkai, Gao Xin, Zhang Siqi, Sun Zhicheng, Liu Ruping, Hu Kuan
School of Printing and Packaging Engineer, Beijing Institute of Graphic Communication, Beijing 102600, China.
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Pharmaceutics. 2024 Feb 29;16(3):345. doi: 10.3390/pharmaceutics16030345.
Fibroblast activation protein (FAP) is a serine protease characterized by its high expression in cancer-associated fibroblasts (CAFs) and near absence in adult normal tissues and benign lesions. This unique expression pattern positions FAP as a prospective biomarker for targeted tumor radiodiagnosis and therapy. The advent of FAP-based radiotheranostics is anticipated to revolutionize cancer management. Among various types of FAP ligands, peptides and antibodies have shown advantages over small molecules, exemplifying prolonged tumor retention in human volunteers. Within its scope, this review summarizes the recent research progress of the FAP radiopharmaceuticals based on antibodies and peptides in tumor imaging and therapy. Additionally, it incorporates insights from recent studies, providing valuable perspectives on the clinical utility of FAP-targeted radiopharmaceuticals.
成纤维细胞活化蛋白(FAP)是一种丝氨酸蛋白酶,其特征在于在癌症相关成纤维细胞(CAF)中高表达,而在成人正常组织和良性病变中几乎不存在。这种独特的表达模式使FAP成为靶向肿瘤放射性诊断和治疗的潜在生物标志物。基于FAP的放射诊疗学的出现有望彻底改变癌症管理。在各种类型的FAP配体中,肽和抗体已显示出优于小分子的优势,例如在人类志愿者中肿瘤保留时间延长。在此范围内,本综述总结了基于抗体和肽的FAP放射性药物在肿瘤成像和治疗方面的最新研究进展。此外,它纳入了近期研究的见解,为FAP靶向放射性药物的临床应用提供了有价值的观点。